annb0t
Top 20
It's been a soft week for Clinuvel Pharmaceuticals Limited (ASX:CUV) shares, which are down 14%. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be happy with the 206% return, over that period. We think it's more important to dwell on the long term returns than the short term returns. The more important question is whether the stock is too cheap or too expensive today. Unfortunately not all shareholders wi...
>>> Read more: Clinuvel Pharmaceuticals' (ASX:CUV) earnings growth rate lags the 25% CAGR delivered to shareholders
>>> Read more: Clinuvel Pharmaceuticals' (ASX:CUV) earnings growth rate lags the 25% CAGR delivered to shareholders
